1. Home
  2. CGON vs AGX Comparison

CGON vs AGX Comparison

Compare CGON & AGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • AGX
  • Stock Information
  • Founded
  • CGON 2010
  • AGX 1961
  • Country
  • CGON United States
  • AGX United States
  • Employees
  • CGON N/A
  • AGX N/A
  • Industry
  • CGON
  • AGX Engineering & Construction
  • Sector
  • CGON
  • AGX Consumer Discretionary
  • Exchange
  • CGON NYSE
  • AGX Nasdaq
  • Market Cap
  • CGON 2.1B
  • AGX 2.1B
  • IPO Year
  • CGON 2024
  • AGX N/A
  • Fundamental
  • Price
  • CGON $25.55
  • AGX $203.40
  • Analyst Decision
  • CGON Strong Buy
  • AGX Buy
  • Analyst Count
  • CGON 10
  • AGX 2
  • Target Price
  • CGON $64.44
  • AGX $193.00
  • AVG Volume (30 Days)
  • CGON 784.3K
  • AGX 539.9K
  • Earning Date
  • CGON 08-07-2025
  • AGX 06-04-2025
  • Dividend Yield
  • CGON N/A
  • AGX 0.74%
  • EPS Growth
  • CGON N/A
  • AGX 154.06
  • EPS
  • CGON N/A
  • AGX 7.14
  • Revenue
  • CGON $662,000.00
  • AGX $910,157,000.00
  • Revenue This Year
  • CGON N/A
  • AGX $10.87
  • Revenue Next Year
  • CGON $14,719.70
  • AGX $18.35
  • P/E Ratio
  • CGON N/A
  • AGX $28.42
  • Revenue Growth
  • CGON 224.51
  • AGX 45.08
  • 52 Week Low
  • CGON $14.80
  • AGX $63.53
  • 52 Week High
  • CGON $40.47
  • AGX $246.60
  • Technical
  • Relative Strength Index (RSI)
  • CGON 48.31
  • AGX 49.53
  • Support Level
  • CGON $25.02
  • AGX $210.08
  • Resistance Level
  • CGON $26.97
  • AGX $228.75
  • Average True Range (ATR)
  • CGON 1.14
  • AGX 12.84
  • MACD
  • CGON -0.18
  • AGX -4.08
  • Stochastic Oscillator
  • CGON 17.79
  • AGX 18.15

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About AGX Argan Inc.

Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.

Share on Social Networks: